![](https://endpts.com/wp-content/uploads/2019/06/Screen-Shot-2019-06-01-at-6.02.48-PM.png)
#ASCO19: Struggling Nektar braves a tough crowd to offer up 4 new CRs for skin cancer drug
CHICAGO — Nektar Therapeutics $NKTR came back to ASCO looking for some redemption after their pratfall on their NKTR-214 presentation here last year — causing damage to the share price that has yet to be repaired. And while they are a long way from being back in the good graces of the analysts, its top researchers are making a determined march ahead with what they still believe is a game-changing cancer therapy well worth Bristol-Myers’ blockbuster buy-in.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.